Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

• Published in: The New England journal of medicine Vol. 382; no. 10; pp. 893 - 902
• Main Authors: Conradie, Francesca, Diacon, Andreas H, Ngubane, Nosipho, Howell, Pauline, Everitt, Daniel, Crook, Angela M, Mendel, Carl M, Egizi, Erica, Moreira, Joanna, Timm, Juliano, McHugh, Timothy D, Wills, Genevieve H, Bateson, Anna, Hunt, Robert, Van Niekerk, Christo, Li, Mengchun, Olugbosi, Morounfolu, Spigelman, Melvin
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 05.03.2020
• Subjects: Administration, Oral; Adolescent; Adult; Antitubercular Agents - administration & dosage; Antitubercular Agents - adverse effects; Bacterial infections; Bacterial Load; Bactericidal activity; Diarylquinolines - administration & dosage; Diarylquinolines - adverse effects; Drug dosages; Drug resistance; Drug Therapy, Combination; Enrollments; Extensively Drug-Resistant Tuberculosis - drug therapy; Extensively Drug-Resistant Tuberculosis - mortality; FDA approval; Female; Humans; Intention to Treat Analysis; Laboratories; Linezolid; Linezolid - administration & dosage; Linezolid - adverse effects; Male; Middle Aged; Multidrug resistance; Mycobacterium tuberculosis - isolation & purification; Myelosuppression; Nitroimidazoles - administration & dosage; Nitroimidazoles - adverse effects; Oral administration; Patients; Peripheral neuropathy; Protein synthesis; Safety; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant - drug therapy; Tuberculosis, Pulmonary - drug therapy; Young Adult; South Africa

Treatment options for highly drug-resistant tuberculosis are limited. In this study in South Africa, a new agent, pretomanid, was combined with bedaquiline and linezolid for a 26-week course to treat extensively drug-resistant and complicated multidrug-resistant pulmonary TB. Although there were tox...